WebinarsNew
Deep DiveNew
Explore Business Standard
WebinarsNew
Deep DiveNew
Explore Business Standard
The revenue stands at ₹9,150.35 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.35 per cent from ₹8,853.34 crore. This corresponds to a year-on-year *(YoY) growth of 16.30 per cent.
Operating Profit stands at ₹1,839.34 crore, reflecting a quarter-on-quarter *(QoQ) increase of 5.08 per cent from ₹1,750.35 crore. This corresponds to a year-on-year *(YoY) growth of 14.74 per cent.
PBDT stands at ₹2,001.91 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.15 per cent from ₹1,769.18 crore. This corresponds to a year-on-year *(YoY) growth of 24.15 per cent.
Profit Before Tax stands at ₹1,515.09 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.39 per cent from ₹1,290.61 crore. This corresponds to a year-on-year *(YoY) growth of 25.55 per cent.
Net Profit stands at ₹1,032.03 crore, reflecting a quarter-on-quarter *(QoQ) increase of 12.07 per cent from ₹920.84 crore. This represents a 25.22 per cent year-on-year *(YoY) growth for the same year.
| Category | Q1 FY26-27 | Q1 FY25-26 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 9,150.35 | 7,868.14 | 16.30 | 33,653.08 | 31,723.73 | 6.08 |
| Expenses | 7,311.01 | 6,265.11 | 16.69 | 26,872.68 | 25,172.63 | 6.75 |
| Other Income | 264.23 | 107.22 | 146.44 | 493.61 | 621.85 | -20.62 |
| Operating Profit | 1,839.34 | 1,603.03 | 14.74 | 7,274.01 | 7,172.95 | 1.41 |
| Depreciation | 486.82 | 405.70 | 20.00 | 1,778.19 | 1,649.42 | 7.81 |
| Interest | 101.66 | 97.75 | 4.00 | 383.97 | 457.24 | -16.02 |
| Profit Before Tax | 1,515.09 | 1,206.80 | 25.55 | 5,111.85 | 5,066.29 | 0.90 |
| Tax | 483.06 | 382.60 | 26.26 | 1,736.14 | 1,699.98 | 2.13 |
| Net Profit | 1,032.03 | 824.20 | 25.22 | 3,502.97 | 3,483.57 | 0.56 |
| Category | Q1 FY26-27 | Q1 FY25-26 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 2,799.51 | 2,848.17 | -1.71 | 11,171.72 | 10,933.30 | 2.18 |
| Expenses | 1,917.26 | 2,051.83 | -6.56 | 8,097.16 | 8,375.73 | -3.33 |
| Other Income | 241.89 | 83.77 | 188.75 | 587.53 | 328.12 | 79.06 |
| Operating Profit | 2,660.89 | 2,555.95 | 4.11 | 3,662.09 | 2,885.69 | 26.91 |
| Depreciation | 68.99 | 70.02 | -1.47 | 285.36 | 297.20 | -3.98 |
| Interest | 47.07 | 60.00 | -21.55 | 213.15 | 230.04 | -7.34 |
| Profit Before Tax | 1,008.08 | 750.09 | 34.39 | 3,163.58 | 2,358.45 | 34.14 |
| Tax | 270.86 | 190.96 | 41.84 | 746.82 | 627.37 | 19.04 |
| Net Profit | 737.22 | 559.13 | 31.85 | 2,414.80 | 1,746.79 | 38.24 |
| Category | Q1 FY26-27 | Q4 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 9,150.35 | 8,853.34 | 3.35 |
| Expenses | 7,311.01 | 7,102.99 | 2.93 |
| Other Income | 264.23 | 117.04 | 125.76 |
| Operating Profit | 1,839.34 | 1,750.35 | 5.08 |
| Depreciation | 486.82 | 478.57 | 1.72 |
| Interest | 101.66 | 98.21 | 3.51 |
| Profit Before Tax | 1,515.09 | 1,290.61 | 17.39 |
| Tax | 483.06 | 369.77 | 30.64 |
| Net Profit | 1,032.03 | 920.84 | 12.07 |
| Category | Q1 FY26-27 | Q4 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 2,799.51 | 2,786.55 | 0.47 |
| Expenses | 1,917.26 | 2,005.13 | -4.38 |
| Other Income | 241.89 | 214.09 | 12.99 |
| Operating Profit | 2,660.89 | 2,599.19 | 2.37 |
| Depreciation | 68.99 | 71.93 | -4.09 |
| Interest | 47.07 | 47.27 | -0.42 |
| Profit Before Tax | 1,008.08 | 876.31 | 15.04 |
| Tax | 270.86 | 184.08 | 47.14 |
| Net Profit | 737.22 | 692.23 | 6.50 |
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1.01% | 1.22% | 1.74% | 6.56% | 26.87% | 54.79% |
| Cipla | 0.32% | -0.87% | -4.13% | -7.85% | 11.32% | -11.59% |
| Mankind Pharma | 0.71% | -0.30% | 7.56% | -1.34% | 22.41% | 0.62% |
| Dr Reddy's Labs | 0.20% | -2.07% | 5.72% | -10.59% | 1.18% | -3.10% |
| Lupin | 0.90% | -0.69% | -3.66% | -18.55% | -11.70% | 5.37% |
| Glenmark Pharma. | 0.38% | -0.85% | -6.98% | 1.18% | 8.37% | 16.70% |
| Alkem Lab | 1.46% | 2.23% | 1.56% | -7.13% | 1.88% | -4.15% |
Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i
